- Home
- DXLG vs MAIA Comparison
DXLG vs MAIA Comparison
Compare DXLG & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | MAIA |
|---|---|---|
| Founded | 1976 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2M | 49.3M |
| IPO Year | 1994 | 2022 |
Fundamental Metrics
Financial Performance| Metric | DXLG | MAIA |
|---|---|---|
| Price | $0.49 | $1.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | 124.7K | ★ 1.1M |
| Earning Date | 04-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.53 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $467,015,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.47 | $0.87 |
| 52 Week High | $2.07 | $3.19 |
Technical Indicators
Market Signals| Indicator | DXLG | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 33.93 | 36.42 |
| Support Level | N/A | $1.20 |
| Resistance Level | $0.99 | $1.69 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 3.99 | 10.19 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.